Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 6/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 5/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093985 | 0.83 | ALDH1A1 (0.50) | LMNAKDM4EALDH1A1TSHRKMT2A | |
| SCHEMBL11883949 | 0.81 | POLB (0.55) | SMN1; SMN2LMNAALDH1A1HTR6TSHR | |
| SCHEMBL28113811 | 0.80 | CA2 (0.53) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL5565365 | 0.78 | CA12 (0.54) | SMN1; SMN2LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL11884662 | 0.78 | HTR6 (0.52) | SMN1; SMN2LMNACYP2C19KDM4ENPSR1 | |
| SCHEMBL28335271 | 0.75 | — | — | |
| SCHEMBL28176926 | 0.71 | KMT2A (0.58) | ALDH1A1KMT2ACA1CA2CA9 | |
| SCHEMBL11882075 | 0.71 | L3MBTL1 (0.77) | SMN1; SMN2LMNACYP2C19KDM4ENPSR1 | |
| SCHEMBL20503569 | 0.71 | HTT (0.39) | SMN1; SMN2LMNAKDM4EALDH1A1RAB9A | |
| SCHEMBL11793140 | 0.70 | CA1 (0.85) | CYP2C19ALDH1A1MAPTHTR6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111763172-B | Halosulfuron-methyl hapten and complete antigen as well as preparation method and application thereof | 中国农业科学院农业质量标准与检测技术研究所 | 2022-04-08 | — | — | CN | disclosed |
| CN-111763172-A | Halosulfuron-methyl hapten and complete antigen as well as preparation method and application thereof | 中国农业科学院农业质量标准与检测技术研究所 | 2020-10-13 | — | — | CN | disclosed |
| EP-1257539-B1 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6531478-B2 | For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders | KORDIK CHERYL P (US) | 2003-03-11 | — | — | US | disclosed |
| EP-1257539-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | KORDIK CHERYL P (US) | 2002-05-30 | — | — | US | disclosed |
| WO-2001062737-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-3769076-A | ARYLSULONAMIDOPYRAZOLE AND IMIDAZOLE INTUMESCENT COATED ARTICLES | CITIES SERVICE CO | 1973-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | NPY5R, NPY1R, NPY4R | SMN1; SMN2 4189/4885LMNA 3821/4885CYP2C19 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.